The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity:A Meta-Analysis

Objective Recent studies have indicated potential anti-inflammatory effects of glucagon-like peptide-1 receptor agonists(GLP-1RAs)on asthma,which is often comorbid with type 2 diabetes mellitus(T2DM)and obesity.Therefore,we conducted a meta-analysis to assess the association between the administration of glucagon-like peptide-1(GLP-1)receptor-based agonists and the incidence of asthma in patients with T2DM and/or obesity.Methods PubMed,Web of Science,Embase,the Cochrane Central Register of Controlled Trials,and Clinicaltrial.gov were systematically searched from inception to July 2023.Randomized controlled trials(RCTs)of GLP-1 receptor-based agonists(GLP-1RA,GLP-1 based dual and triple receptor agonist)with reports of asthma events were included.Outcomes were computed as risk ratios(RR)using a fixedeffects model.Results Overall,39 RCTs with a total of 85,755 participants were included.Compared to non-GLP-1 receptor-based agonist users,a trend of reduced risk of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments,although the difference was not statistically significant[RR=0.91,95%confidence interval(CI):0.68 to 1.24].Further Subgroup analyses indicated that the use of light-molecular-weight GLP-1RAs might be associated with a reduced the risk of asthma when compared with non-users(RR=0.65,95%CI:0.43 to 0.99,P=0.043).We also performed sensitivity analyses for participant characteristics,study design,drug structure,duration of action,and drug subtypes.However,no significant associations were observed.Conclusion Compared with non-users,a modest reduction in the incidence of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments.Further investigations are warranted to assess the association between GLP-1 receptor-based agonists and the risk of asthma.

Chemical constituents of Lomatogonium carinthiacum and Halenia corniculata

Objective:To study the chemical constituents from traditional Chinese(Mongolian)medicine,Lomatogonium carinthiacum and Halenia corniculate.Methods:The chemical constituents were isolated and purified by silicagel column,Sephadex LH-20,ODS and high performance liquid chromategramphy.The structures were identified by NMR and MS analysis technics.Results:Twelve compounds were isolated and identified as isovitexin(1),Luteolin-5-O-β-D-glucoside(2),Isosaponarin(3),Luteolin-7-O-β-D-glucoside(4,7),1,4,8-Trimethoxy-xanthone-6-O-β-D-glucoronyl-(1→6)O-β-Dglucoside(5),friginoside D(6),1-hydroxy-2,3,5-trimethoxyxanthone(8),1-hydroxy-2,3,4,5-tet ramethoxyxanthone(9),1-hydroxy-2,3,4,7-tetramethoxyxanthone(10),1-hydroxy-2,3,4,5,7-pentame thoxyxanthone(11)and usnic acid(12).Conclusion:Compounds 6 and 12 are obtained from L.carinthiacum and H.corniculate for the first time.